Patients with indeterminate Chagas Disease (CD) require constant surveillance and care, which has been impeded by the Covid-19 pandemic. Chronic indeterminate CD requires annual cardiac tests as approximately 30-40% of patients develop cardiac or GI complications. Patients may need antiparasitic treatment to disrupt congenital transmission. The course of treatment includes two months of patient monitoring and lab testing to scan for potential side effects. These routine appointments have been hindered by the Covid-19 pandemic due to the risk of SARS-CoV-2 infection in healthcare settings. Additionally, medical personnel and resources have been dedicated to combating the Covid-19 pandemic, contributing to the disparities in treatment for patients with indeterminate CD. Patients with chronic indeterminate CD may develop arrhythmias or cardiovascular issues associated with CCC when an acute infection triggers a cytokine storm.